Effectiveness of Pentavalent and Monovalent Rotavirus Vaccines in Concurrent Use Among US Children <5 Years of Age, 2009–2011
Author(s) -
Daniel C. Payne,
Julie A. Boom,
Mary Allen Staat,
Kathryn M. Edwards,
Peter G. Szilagyi,
Eileen J. Klein,
Rangaraj Selvarangan,
Parvin H. Azimi,
Christopher Harrison,
Mary E. Moffatt,
Samantha Johnston,
Leila C. Sahni,
Carol J. Baker,
Marcia A. Rench,
Stephanie Donauer,
Monica McNeal,
James D. Chappell,
Geoffrey A. Weinberg,
Azadeh Tasslimi,
Jacqueline E. Tate,
Mary E. Wikswo,
Aaron T. Curns,
Iddrisu Sulemana,
Slavica Mijatovic-Rustempasic,
Mathew D. Esona,
Michael D. Bowen,
Jon R. Gentsch,
Umesh D. Parashar
Publication year - 2013
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/cit164
Subject(s) - rotavirus , medicine , rotavirus vaccine , confidence interval , vaccination , pediatrics , genotype , diarrhea , immunology , biology , gene , biochemistry
We assessed vaccine effectiveness (VE) for RotaTeq (RV5; 3 doses) and Rotarix (RV1; 2 doses) at reducing rotavirus acute gastroenteritis (AGE) inpatient and emergency department (ED) visits in US children.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom